BioGend Therapeutics Co., Ltd. (TPEX: 6733)

BioGend Therapeutics Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 2, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	4,461	4,708	2,247	2,757	3,574	2,444
Market Cap Growth	7.41%	109.50%	-18.50%	-22.86%	46.27%	-
Enterprise Value	3,837	3,990	1,720	2,063	3,039	1,954
Last Close Price	35.90	38.25	21.80	26.40	38.34	29.41
PS Ratio	28.21	42.83	71.46	297.47	2565.83	1672.55
PB Ratio	5.09	4.92	3.07	2.92	5.07	4.15
P/TBV Ratio	6.46	6.09	4.73	4.53	5.93	5.20
EV/Sales Ratio	24.50	36.30	54.70	222.54	2181.48	1337.15
Debt / Equity Ratio	0.01	0.01	0.02	0.00	-	-
Asset Turnover	0.16	0.12	0.03	0.01	0.00	0.00
Inventory Turnover	2.04	1.89	1.24	0.64	0.10	0.67
Quick Ratio	24.69	16.90	16.73	28.57	29.27	23.93
Current Ratio	25.33	17.32	17.01	29.24	29.92	25.51
Return on Equity (ROE)	-13.56%	-19.07%	-24.54%	-17.51%	-22.51%	-26.67%
Return on Assets (ROA)	-8.65%	-11.79%	-14.85%	-11.74%	-12.53%	-16.63%
Return on Capital (ROIC)	-9.17%	-12.85%	-16.17%	-12.43%	-12.91%	-17.10%
Earnings Yield	-2.49%	-3.32%	-8.21%	-5.02%	-4.07%	-6.67%
FCF Yield	-2.56%	-3.50%	-8.32%	-4.99%	-3.28%	-6.04%
Buyback Yield / Dilution	-6.78%	-16.69%	-1.77%	-15.90%	-7.56%	-33.88%
Total Shareholder Return	-6.78%	-16.69%	-1.77%	-15.90%	-7.56%	-33.88%

Source: S&P Capital IQ. Standard template. Financial Sources.